→Jump to content

Office of Technology Assessment at the German Bundestag Office of Technology Assessment at the German Bundestag

16.11.2009 | New publication:

Innovative therapies in clinical trials

A TAB innovation report analyses the chances and risks of biomedical innovations in Germany as a location for industry

Clinical research is an important link in the chain of development of new treatment methods. Are the general conditions in Germany adequate to ensure an early access to innovative treatments while at the same time avoiding possible risks for the probands as much as possible? This question was the starting point of an extensive analysis that was performed by TAB on behalf of the Committee for Education, Research and Technology Assessment.

New biotechnology based therapy techniques become increasingly important for economy and for supplying patients with innovative medication. The TAB innovation report (TAB working report No 132) which is now available provides an overview of current research and development of new therapy methods as well as an assessment of (EU wide and national) regulatory frameworks in this area. It is being discussed if the current or future regulations and procedures are suitable to improve the competitiveness as well as if they provide adequate safety of probands and patients and ensure protection from improper application. In a comparative perspective the position of Germany in the international context is being examined.